ExeVir Bio is a company that harnesses a llama-derived antibody technology platform to generate antiviral therapies providing broad protection against coronaviruses. It’s lead candidate, VHH72-Fc, binds to a unique epitope – the part of a molecule to which an antibody attaches itself–in SARS-CoV-1 and SARS-CoV-2 viruses, preventing them from entering the cell.